KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Retained Earnings (2016 - 2025)

Biomarin Pharmaceutical's Retained Earnings history spans 17 years, with the latest figure at -$13.5 million for Q4 2025.

  • For the quarter ending Q4 2025, Retained Earnings rose 93.08% year-over-year to -$13.5 million, compared with a TTM value of -$13.5 million through Dec 2025, up 93.08%, and an annual FY2025 reading of -$13.5 million, up 93.08% over the prior year.
  • Retained Earnings for Q4 2025 was -$13.5 million at Biomarin Pharmaceutical, up from -$33.9 million in the prior quarter.
  • The five-year high for Retained Earnings was $231.5 million in Q2 2025, with the low at -$930.8 million in Q4 2021.
  • Average Retained Earnings over 5 years is -$307.2 million, with a median of -$114.3 million recorded in 2024.
  • Year-over-year, Retained Earnings crashed 82671.78% in 2022 and then surged 763.92% in 2025.
  • Tracing BMRN's Retained Earnings over 5 years: stood at -$930.8 million in 2021, then surged by 99.58% to -$3.9 million in 2022, then crashed by 15973.29% to -$621.6 million in 2023, then soared by 68.68% to -$194.7 million in 2024, then soared by 93.08% to -$13.5 million in 2025.
  • Per Business Quant, the three most recent readings for BMRN's Retained Earnings are -$13.5 million (Q4 2025), -$33.9 million (Q3 2025), and $231.5 million (Q2 2025).